Wedbush analyst Laura Chico raised the firm's price target on Travere Therapeutics to $55 from $53 and keeps an Outperform rating on the shares. Despite the Q1 Filspari miss, the firm sees a number of positive forward signals that should keep investors looking ahead to the FSGS launch. First, Patient Start Forms reached a new high and reflected pure IgAN demand. With other agents launching and continued interest, Wedbush sees market expansion and no signs that this may slow in the near term.
